Literature DB >> 31383675

Hypercalcaemia, renal dysfunction, anaemia and bone lesions (CRAB) do not always represent multiple myeloma: diffuse large B cell lymphoma presenting with CRAB symptoms in a 69-year-old man.

Hafez Mohammad Ammar Abdullah1, Moataz Ellithi1, Qazi Waqas1, Arwyn Cunningham2, Tony Oliver1.   

Abstract

Hypercalcaemia, renal dysfunction, anaemia and bone lesions (CRAB) are a constellation of signs and symptoms that are collectively referred to as the CRAB features. When present together, multiple myeloma (MM) should be at the top of the differential diagnosis. We present a 69-year-old man who presented with severe body aches and bone pain in his ribs and pelvis, associated with fatigue and constipation. He was found to have hypercalcaemia, acute kidney injury, anaemia and numerous lytic lesion on chest imaging. Physical examination and imaging were unremarkable for any enlarged lymph nodes. The patient was initially suspected to have multiple myeloma, however, serum and urine protein electrophoresis, and serum free light chain assays were negative. The patient was ultimately diagnosed with diffuse large B cell lymphoma based on a bone marrow biopsy. This case highlights the fact that presence of hypercalcaemia, renal dysfunction, anaemia and bone lesions are not usually specific for MM. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; oncology

Mesh:

Year:  2019        PMID: 31383675      PMCID: PMC6685385          DOI: 10.1136/bcr-2018-229070

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  34 in total

1.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.

Authors:  Hironobu Shibata; Masahiro Abe; Kenji Hiura; Javier Wilde; Keiji Moriyama; Toshiaki Sano; Ken-Ichi Kitazoe; Toshihiro Hashimoto; Shuji Ozaki; Shingo Wakatsuki; Shinsuke Kido; Daisuke Inoue; Toshio Matsumoto
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

3.  Precursor B lymphoblastic lymphoma presenting as lytic bone lesions.

Authors:  S Iravani; T P Singleton; C W Ross; B Schnitzer
Journal:  Am J Clin Pathol       Date:  1999-12       Impact factor: 2.493

4.  Primary multifocal lymphoma of bone presenting as hypercalcemic crisis: report of a rare manifestation of extranodal lymphoma.

Authors:  E Evron; S Goland; A Klepfish; S D Malnick; N Sokolowski; Z M Sthoeger
Journal:  Leuk Lymphoma       Date:  1999-06

5.  CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.

Authors:  Graham W Slack; Christian Steidl; Laurie H Sehn; Randy D Gascoyne
Journal:  Br J Haematol       Date:  2014-08-19       Impact factor: 6.998

Review 6.  Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.

Authors:  Sakae Tanaka; Kozo Nakamura; Naoyuki Takahasi; Tatsuo Suda
Journal:  Immunol Rev       Date:  2005-12       Impact factor: 12.988

Review 7.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

8.  Diffuse large B-cell lymphoma presenting with hypercalcemia and multiple osteolysis.

Authors:  Yoshiko Matsuhashi; Taizo Tasaka; Eisuke Uehara; Miharu Fujimoto; Mitsuhiro Fujita; Takahiro Tamura; Tohru Honda; Minoru Kuwajima; Yasumasa Shimoura; Shohei Mano; Masami Nagai; Toshihiko Ishida
Journal:  Leuk Lymphoma       Date:  2004-02

9.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

Review 10.  Pathophysiology of myeloma bone disease.

Authors:  Flavia R Esteve; G David Roodman
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

View more
  2 in total

Review 1.  Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.

Authors:  Hirotaka Mori; Masahiko Fukatsu; Hiroshi Ohkawara; Yuka Oka; Yuki Kataoka; Shunsuke Taito; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2021-08-30       Impact factor: 2.490

2.  Hypercalcaemia, Renal Dysfunction, Anaemia, Bone Disease (CRAB Criteria): A Case of Lymphoma.

Authors:  Balraj Singh; Pooja Gogia; Parminder Kaur; Nirmal Guragai; Michael Maroules
Journal:  Eur J Case Rep Intern Med       Date:  2020-12-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.